Why the study?
The study was conducted to evaluate the effectiveness of a decision-making module in selecting an oral anticoagulant for patients with atrial fibrillation.
Does a decision-making module aid in the personalized selection of oral anticoagulants for patients with atrial fibrillation?
Does a decision-making module aid in the personalized selection of oral anticoagulants for patients with atrial fibrillation?
Answers are grounded in this paper and cite their sources.
A personalized decision-making module incorporating multiple clinical risk scores can guide the specific selection of oral anticoagulants in patients with atrial fibrillation.
Aim To evaluate the effectiveness of the decision-making module in selecting an oral anticoagulant for patients with atrial fibrillation.Material and methods 638 patients with atrial fibrillation aged 68.2±4.5 years were evaluated. The CHA2DS2-VASc, HAS-BLED, and 2MАСЕ scales, the creatinine clearance calculator, and the Morisky-Green questionnaire were used.Results 311 (48.75 %) patients had paroxysmal atrial fibrillation, 138 (21.6%) had persistent atrial fibrillation, 44 (22.7%) had long-standing persistent atrial fibrillation, and 145 (22.7 %) had permanent atrial fibrillation. Mean CHADS2‑VASc scale score was 4.82; НAS-BLED scale score was 2.9; 2MACE score was 2.28; and compliance score was 3.52. 172 (26.9 %) patients were treated with rivaroxaban; 166 (26 %), with apixaban; 84 (13.2 %), with dabigatran; 210 (32.9 %), with warfarin; and 6 (1 %), with acetylsalicylic acid.Conclusion The developed decision-making module is based on scientific justification of personalized selection of the oral anticoagulant and updates the knowledge on major issues of prescription.
No takes yet. Share an insight, caveat, or question.
Горбунова et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: